M&A Deal Summary

Biosynth Acquires vivitide

On March 17, 2022, Biosynth acquired life science company vivitide from Ampersand Capital Partners

Acquisition Highlights
  • This is Biosynth’s 2nd transaction in the Life Science sector.
  • This is Biosynth’s 1st transaction in the United States.
  • This is Biosynth’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2022-03-17
Target vivitide
Sector Life Science
Buyer(s) Biosynth
Sellers(s) Ampersand Capital Partners
Deal Type Add-on Acquisition

Target

vivitide

Gardner, Massachusetts, United States
vivitide is a provider of custom peptide synthesis services, custom antibodies, catalog peptides, and biochemicals to academia, pharmaceutical, biotech, and diagnostic companies worldwide. vivitide was founded in 1998 and is based in Gardner, Massachusetts.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Biosynth

St. Gallen, Switzerland
Category Company
Founded 1965
Sector Chemicals
DESCRIPTION

Biosynth is a fully hybrid research products, life sciences reagents and custom synthesis and manufacturing services company with global research, manufacturing and distribution facilities. They are the supplier of choice for many in the pharmaceutical, life science, food, agrochemical, cosmetic and diagnostic sectors and manufacture and source a vast range of chemical and biochemical products. Biosynth was formed in 1965 and is based in St. Gallen, Switzerland.

DEAL STATS #
Overall 2 of 8
Sector (Life Science) 2 of 7
Type (Add-on Acquisition) 2 of 8
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2022) 2 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-01-01 EUCODIS Bioscience

Vienna, Austria

EUCODIS Biosciencedevelops, customizes, manufactures, and markets industrial enzymes. EUCODIS Bioscience’ products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties. The Company offers a broad portfolio of novel enzymes, including lipases, phospholipases, and beta-lactamases. EUCODIS Bioscience is based in Vienna, Austria.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-05-26 Aalto Bio Reagents

Dublin, Ireland

Aalto Bio Reagents is a developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in emerging diseases. Aalto Bio Reagents was founded in 1978 and is based in Dublin, Ireland.

Buy -

Seller(S) 1

SELLER

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1988
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.

DEAL STATS #
Overall 51 of 55
Sector (Life Science) 23 of 25
Type (Add-on Acquisition) 37 of 38
State (Massachusetts) 14 of 14
Country (United States) 49 of 51
Year (2022) 4 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-03-01 BioEcho Life Sciences

Koln, Germany

BioEcho Life Sciences specializes in nucleic acid sample preparation tools for clinical, biotech, life sciences research, agricultural, and industrial applications. BioEcho Life Sciences was formed in 2016 and is based in Koln, Germany.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-04-18 Syft

Christchurch , New Zealand

Syft develops SIFT-MS, a form of direct mass spectrometry that analyses volatile organic compounds (VOCs) in the air with typical detection limits at parts-per-trillion level (by volume; pptv). Syft was founded in 2002 and is based in Christchurch, New Zealand.

Buy -
Mergr

Product

Company

Legal